Press Releases

 Sep 29, 2022, 13:31 ET  CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the Company will participate in the Ladenburg Thalmann Healthcare Conference on September 29, 2022. Carl Spana, […]

 Sep 22, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Gross product sales increased 79%, net product revenue increased 257% and prescriptions dispensed increased 49%,

 Sep 19, 2022, 16:15 ET  CRANBURY, N.J., Sept. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted

 Sep 08, 2022, 07:30 ET  Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable Treatment Option for Ulcerative Colitis Patients CRANBURY, N.J., Sept. 8, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical

 Aug 19, 2022, 07:30 ET  Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that

 Aug 16, 2022, 07:30 ET  Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Patients to be Enrolled No Safety Concerns Identified Topline Results Currently Expected Second Quarter Calendar 2023 CRANBURY, N.J., Aug. 16, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN),

Jul 26, 2022, 07:30 ET Gross product sales increased 75% andPrescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J., July 26, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced preliminary fourth quarter

May 17, 2022, 07:30 ET Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® – Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarter Closed on a

May 12, 2022, 08:00 ET CRANBURY, N.J., May 12, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin” or the “Company”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced  that it has entered into a securities purchase agreement with institutional investors

May 11, 2022, 09:02 ET CRANBURY, N.J., May 11, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its